Pfizer Ltd banner

Pfizer Ltd
NSE:PFIZER

Watchlist Manager
Pfizer Ltd Logo
Pfizer Ltd
NSE:PFIZER
Watchlist
Price: 4 722 INR -1.28% Market Closed
Market Cap: ₹216B

Pfizer Ltd
Cash from Financing Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Pfizer Ltd
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Pfizer Ltd
NSE:PFIZER
Cash from Financing Activities
-₹8B
CAGR 3-Years
-34%
CAGR 5-Years
13%
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Cash from Financing Activities
-₹13.3B
CAGR 3-Years
14%
CAGR 5-Years
-2%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Cash from Financing Activities
-₹14.3B
CAGR 3-Years
-16%
CAGR 5-Years
-5%
CAGR 10-Years
N/A
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Cash from Financing Activities
-₹17.5B
CAGR 3-Years
-25%
CAGR 5-Years
17%
CAGR 10-Years
N/A
Lupin Ltd
NSE:LUPIN
Cash from Financing Activities
₹14.5B
CAGR 3-Years
103%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Cash from Financing Activities
-₹19.1B
CAGR 3-Years
-10%
CAGR 5-Years
-6%
CAGR 10-Years
N/A
No Stocks Found

Pfizer Ltd
Glance View

Pfizer Ltd., a giant in the pharmaceutical industry, has woven its identity deeply into the fabric of healthcare innovation. Established initially to create chemical compounds, it evolved into a pharmaceutical pioneer through a series of strategic developments and acquisitions. Headquartered in New York, the company has a sprawling international presence, with an intricate network of research facilities, manufacturing plants, and marketing offices spread across the globe. This global footprint empowers Pfizer to leverage diverse talent and resources, driving innovation and efficiency. At the core of Pfizer’s operations is its research and development engine, a crucial element that churns out new medicines and therapies. By investing heavily in R&D, absorbing over $8 billion annually, the company relentlessly pursues breakthroughs in areas such as oncology, vaccines, rare diseases, and primary care, consistently bringing advanced treatments from laboratories to clinics. The way Pfizer sustains its financial health is as much about strategic foresight as it is about scientific prowess. Its revenue streams are crafted through a mix of patent-protected pharmaceuticals, consumer health products, and vaccines. The blockbuster drug era, epitomized by the success of Lipitor, showcased its capability to capture market leadership efficiently. More recently, Pfizer's collaboration with BioNTech on the COVID-19 vaccine highlighted its agility and strategic partnerships. Such initiatives solidify its position in the market and open lucrative opportunities. Beyond products, Pfizer employs a robust marketing strategy and leverages an extensive distribution network to ensure these innovations reach a global clientele efficiently. Through a combination of smart financial management, cutting-edge research, and decisive partnerships, Pfizer Ltd. has positioned itself as a towering figure in the pharmaceutical landscape, capable of responding to global health challenges while ensuring sustainable growth.

PFIZER Intrinsic Value
3 306.58 INR
Overvaluation 30%
Intrinsic Value
Price ₹4 722

See Also

What is Pfizer Ltd's Cash from Financing Activities?
Cash from Financing Activities
-8B INR

Based on the financial report for Dec 31, 2025, Pfizer Ltd's Cash from Financing Activities amounts to -8B INR.

What is Pfizer Ltd's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
13%

Over the last year, the Cash from Financing Activities growth was -283%. The average annual Cash from Financing Activities growth rates for Pfizer Ltd have been -34% over the past three years , 13% over the past five years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett